OBJECTIVE： To investigate the effects of salvianolate combined with bezafibrate on clinical efficacy， inflammatory factors and ventricular function of patients with ischemic cardiomyopathy， and the safety. METHODS： A total of 138 patients with ischemic cardiomyopathy selected from our hospital during Mar. 2015-Mar. 2016 were randomly divided into observation group and control group according to random number table， with 69 cases in each group. Control group was given Bezafibrate dispersible tablets 0.2 g， po， tid. Observation group was additionally given Salvianolate for injection 200 mg added into 0.9％ Sodium chloride injection 250 mL， ivgtt， qd， on the basis of control group. A treatment course lasted for 14 d， and both groups received 2 courses of treatment. Clinical efficacies， the levels of serum inflammatory factors （CRP， TNF-α， IL-6， MMP-9， MCP-1）， ventricular function parameters （LVESD， LVEDD， LVEF） were compared between 2 group. The occurrence of ADR was recorded. RESULTS： Total response rate of observation group （97.10％） was significantly higher than that of control group （86.96％）， with statistical significance （P＜0.05）. Before treatment， there was no statistical significance in serum levels of CRP， TNF-α， IL-6， MMP-9， MCP-1， LVESD， LVEDD and LVEF between 2 groups （P＞0.05）. After treatment， the levels of CRP， TNF-α， IL-6， MMP-9， MCP-1， LVESD and LVEDD in 2 groups were decreased significantly， while LVEF level was decreased significantly； the improvement of observation group was more significant than that of control group， with statistical significance （P＜0.05）. No serious ADR was found in 2 groups during treatment. CONCLUSIONS： Salvianolate combined with bezafibrate have significant therapeutic efficacy for ischemic cardiomyopathy， reduce serum inflammatory factor level and improve ventricular function with good safety.